Baylor University researchers have published a novel approach to fight colorectal cancer, using modified bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. Michael S.

Breakthrough immunotherapy trials are showing unprecedented responses in a subset of rectal cancer patients, hinting at a ...

Colorectal cancer is increasing in younger patients and is now the leading cause of cancer death in those under age 50, yet those patients lack support.

WACO, Texas - Baylor University researchers have published a novel approach to fight colorectal cancer, using modified bacteria as a courier to ...

At the scientific symposium "A Revolution with Biosimilars," organized by the Vietnam Cancer Association and Pfizer Vietnam on March 6-7, 2026, in Hanoi and Ho Chi Minh City, experts discussed ...

In Britain young people are now considered one of the most at-risk groups of bowel cancer , but experts say diet, lifestyle, ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

Amber kept going back to doctors with her symptoms but was told there was nothing wrong ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

DNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS. Posttreatment surveillance remains one of the most ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS ...